Polymorphism of peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala in the Iranian population: Relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes

Namvaran, Fatemeh; Azarpira, Negar; Rahimi‐Moghaddam, Parvaneh; Dabbaghmanesh, Mohammad Hossein

doi:10.1016/j.ejphar.2011.09.158

Cited by 38 publications

(30 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A meta-analysis [30] reported that G allele carriers had a greater protective effect against type 2 diabetes in Asians but not in Europeans or North Americans, as well as a greater protection in lower BMI individuals. The BMIs (mean±SD) was 25.15±2.77 kg/m 2 in our study, 26.43±4.6 kg/m 2 in another Chinese population study [27] , 27.45±4.23 kg/m 2 in an Iranian population study [28] and 31.0±3.3 kg/m 2 in the Caucasian population study [29] . Subjects with lower BMI and carrying G allele of rs1801282 polymorphism showed better pioglitazone efficacy in Asians [27,28] but not in the Caucasian population with a higher BMIs [29] .…”

Section: Wwwchinapharcom Pei Q Et Almentioning

confidence: 89%

“…The BMIs (mean±SD) was 25.15±2.77 kg/m 2 in our study, 26.43±4.6 kg/m 2 in another Chinese population study [27] , 27.45±4.23 kg/m 2 in an Iranian population study [28] and 31.0±3.3 kg/m 2 in the Caucasian population study [29] . Subjects with lower BMI and carrying G allele of rs1801282 polymorphism showed better pioglitazone efficacy in Asians [27,28] but not in the Caucasian population with a higher BMIs [29] . Therefore, the BMI difference in various ethnic groups may be one of the important ethnic factors, which influenced the effect of PPAR-γ2 rs1801282 polymorphism on pioglitazone response.…”

Section: Wwwchinapharcom Pei Q Et Almentioning

confidence: 89%

“…Another study on Chinese Han population also revealed that patients with the CG+GG genotypes of the rs1801282 polymorphism were more likely to have a positive response to pioglitazone than patients with the CC genotype [27] . Namvaran et al [28] determined that the therapeutic response of Iranian diabetic patients with the CG genotype was better than those with the CC genotype, although the difference between groups did not reach statistical significance. Our results were in accordance with the above findings.…”

Section: Wwwchinapharcom Pei Q Et Almentioning

confidence: 99%

See 2 more Smart Citations

PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China

et al. 2012

View full text Add to dashboard Cite

Aim: To investigate the influence of peroxisome proliferator-activated receptor γ2 (PPAR-γ2) gene polymorphism rs1801282 and protein tyrosine phosphatase receptor type D (PTPRD) gene polymorphism rs17584499 on the occurrence of type 2 diabetes and pioglitazone efficacy in a Chinese Han population. Methods: One hundred ninety seven type 2 diabetes patients and 212 healthy controls were enrolled. Among them, 67 type 2 diabetes patients were administered pioglitazone (30 mg/d, po) for 3 months. All the subjects were genotyped for genetic variants in PPAR-γ2 and PTPRD using MALDI-TOF mass spectrometry. Fasting plasma glucose, postprandial plasma glucose, glycated hemoglobin, serum triglyceride, total cholesterol, low-density and high-density lipoprotein-cholesterol were determined. Results: The PPAR-γ2 gene rs1801282 polymorphism was significantly associated with type 2 diabetes susceptibility (OR=0.515, 95% CI 0.268-0.990) and the PTPRD gene rs17584499 polymorphism was also significantly associated with type 2 diabetes (OR=1.984, 95% CI 1.135-3.469) in a dominant model adjusted for age, gender and BMI. After pioglitazone treatment for 3 months, the type 2 diabetes patients with PPAR-γ2 rs1801282 CG genotypes significantly showed higher differential values of postprandial plasma glucose and serum triglyceride compared with those with rs1801282 CC genotype. The patients with PTPRD rs17584499 CT+TT genotypes showed significantly lower differential value of postprandial plasma glucose compared to those with rs17584499 CC genotype. Conclusion: Diabetes risk alleles in PPAR-γ2 (rs1801282) and PTPRD (rs17584499) are associated with pioglitazone therapeutic efficacy.

show abstract

Section: Wwwchinapharcom Pei Q Et Almentioning

confidence: 89%

Section: Wwwchinapharcom Pei Q Et Almentioning

confidence: 89%

Section: Wwwchinapharcom Pei Q Et Almentioning

confidence: 99%

See 1 more Smart Citation

PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China

et al. 2012

View full text Add to dashboard Cite

show abstract

“…According to the results of a previous study on the genotypic frequency of the PPARγ Pro12Ala polymorphism in Iranian T2DM subjects (5.94%) [30], we recruited 465 T2DM patients who met the study criteria from outpatient diabetic centers via phone call and initially screened them for the presence of the polymorphism. In order to gain additional information on the treatment, a 2:1 allocation rate was used [31].…”

Section: Methodsmentioning

confidence: 99%

Docosahexaenoic Acid-Rich Fish Oil Supplementation Improves Body Composition without Influence of the PPARγ Pro12Ala Polymorphism in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

et al. 2015

View full text Add to dashboard Cite

Background: The aims of this research were to investigate (1) the impact of docosahexaenoic acid (DHA)-rich fish oil supplementation on body composition, plasma adiponectin level, and peroxisome proliferator-activated receptor γ (PPARγ) gene expression, and (2) whether the effect of DHA-rich fish oil supplementation on the aforementioned variables is modulated by PPARγ Pro12Ala polymorphism. Methods: We genotyped PPARγ Pro12Ala polymorphism in subjects with type 2 diabetes mellitus (T2DM). Ala carriers and non-Ala carriers were randomly assigned to DHA-rich fish oil or placebo intake for 8 weeks. Results: Glycemic control was not affected by the intervention. The supplementation with DHA-rich fish oil decreased waist circumference (p < 0.001), body fat mass (p = 0.01), body fat percent (p = 0.04), and visceral fat rating (p = 0.02) as well as trunk fat mass (p = 0.04). Weight, body mass index, fat-free mass, adiponectin level, and PPARγ gene expression changes showed no significant difference. No gene-diet interaction was found on body composition, adiponectin level, and PPARγ gene expression. Conclusions: DHA-rich fish oil supplementation favorably modulated body composition in patients with T2DM and could be useful to reduce visceral obesity. However, the PPARγ Pro12Ala polymorphism did not influence the changes in the desired variables.

show abstract

“…The therapeutic efficacy of pioglitazone showed individual differences. It has been proved that T2DM patients with different peroxisome proliferator-activated receptor-γ [15] or resistin [16] genotypes showed distinctive effects in multiple-dose pioglitazone therapy.…”

Section: Introductionmentioning

confidence: 99%

The Effect of <b><i>IGF2BP2</i></b> Gene Polymorphisms on Pioglitazone Response in Chinese Type 2 Diabetes Patients

et al. 2014

View full text Add to dashboard Cite

Background: Genome-wide association studies identified that insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) genetic polymorphisms are related to type 2 diabetes mellitus (T2DM) in several populations. This study aimed to investigate whether the IGF2BP2 gene rs1470579 and rs4402960 polymorphisms were associated with T2DM and pioglitazone efficacy in Chinese T2DM patients. Methods: A total of 281 T2DM patients and 111 healthy volunteers were enrolled to identify the IGF2BP2 gene rs1470579 and rs4402960 polymorphisms; 86 patients were randomly selected and given a 12-week pioglitazone treatment (30 mg/day). Fasting plasma glucose, postprandial plasma glucose (PPG), glycated hemoglobin, serum triglycerides (TG), total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol (HDL-C) were determined before and after pioglitazone treatment. Results: The results showed that the IGF2BP2 gene rs1470579 and rs4402960 polymorphisms were associated with T2DM in a Chinese population (OR = 2.002, 95% CI 1.170-3.426, p < 0.05; OR = 1.879, 95% CI 1.110-3.182, p < 0.05). The effect of pioglitazone on PPG (p < 0.05), TG (p < 0.01) and HDL-C (p < 0.05) was lower in patients with the rs1470579 AC+CC genotypes than in AA genotype carriers. Its effect on PPG level was also lower in patients with the GT+TT genotypes of rs4402960 than in patients with the GG genotype (p < 0.05). Conclusions: The IGF2BP2 gene rs1470579 and rs4402960 polymorphisms were associated with T2DM and therapeutic efficacy of pioglitazone in this Chinese population. i 2014 S. Karger AG, Basel

show abstract

Polymorphism of peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala in the Iranian population: Relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes

Cited by 38 publications

References 35 publications

PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China

PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China

Docosahexaenoic Acid-Rich Fish Oil Supplementation Improves Body Composition without Influence of the PPARγ Pro12Ala Polymorphism in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

The Effect of <b><i>IGF2BP2</i></b> Gene Polymorphisms on Pioglitazone Response in Chinese Type 2 Diabetes Patients

Contact Info

Product

Resources

About

Polymorphism of peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala in the Iranian population: Relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes

Cited by 38 publications

References 35 publications

PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China

PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China

Docosahexaenoic Acid-Rich Fish Oil Supplementation Improves Body Composition without Influence of the PPAR&#947; Pro12Ala Polymorphism in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

The Effect of <b><i>IGF2BP2</i></b> Gene Polymorphisms on Pioglitazone Response in Chinese Type 2 Diabetes Patients

Contact Info

Product

Resources

About

Docosahexaenoic Acid-Rich Fish Oil Supplementation Improves Body Composition without Influence of the PPARγ Pro12Ala Polymorphism in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial